GLP-1 Microdosing and Peripheral Artery Disease: Leg Circulation, Walking Distance, and What the STRIDE Trial Found
Calf pain that stops a walk after two blocks is one of the most underdiagnosed signs of atherosclerosis. In 2025, a GLP-1 medication became the first drug in years to improve walking distance in a large trial of people with that symptom. Here is what the study showed, and what it does not tell anyone about a microdose.
236M
ADULTS WORLDWIDE ESTIMATED TO HAVE PERIPHERAL ARTERY DISEASE (SONG, LANCET GLOBAL HEALTH 2019)
13%
GREATER IMPROVEMENT IN MAXIMUM WALKING DISTANCE WITH SEMAGLUTIDE 1.0 MG VS PLACEBO (STRIDE, LANCET 2025)
0.90
ANKLE-BRACHIAL INDEX AT OR BELOW WHICH PAD IS DIAGNOSED (ACC/AHA GUIDELINE)
A 63-year-old retired electrician with type 2 diabetes told his doctor he had started taking the dog out in short loops. His right calf cramped after about 300 meters, eased after a minute standing still, and came back at the same spot on the next lap. He assumed it was age. His ankle-brachial index came back at 0.72.
Peripheral artery disease, or PAD, is atherosclerosis in the arteries of the legs. The plaque that narrows coronary arteries narrows leg arteries too, and the leg muscles run short of oxygen when they work harder. PAD is common, frequently missed, and closely tied to the same metabolic risks that bring people to GLP-1 medications. This article covers what the research shows about GLP-1 drugs and leg circulation, with a clear line between the full-dose trial data and the untested question of microdosing.
Key takeaways
- •Peripheral artery disease affects an estimated 236 million adults worldwide, and smoking and diabetes are its two strongest risk factors.
- •In the STRIDE trial (Lancet, 2025), 792 adults with type 2 diabetes and claudication who took semaglutide 1.0 mg weekly for 52 weeks improved maximum walking distance about 13 percent more than those on placebo.
- •GLP-1 receptor agonists have not shown an amputation signal in outcome trials; a LEADER analysis linked liraglutide to a hazard ratio of about 0.65 for amputation.
- •No trial has tested a GLP-1 microdose for PAD, so the STRIDE result cannot be assumed to apply at doses several times lower.
- •Supervised walking for at least 12 weeks, stopping smoking, and statin and antiplatelet therapy remain the foundation of PAD care in the 2024 ACC/AHA guideline.
What is peripheral artery disease, and who gets it?
Peripheral artery disease is a narrowing of the arteries that supply the legs, caused in almost all cases by atherosclerotic plaque. A 2019 analysis in The Lancet Global Health by Peige Song and colleagues estimated that about 236 million adults aged 25 and older had PAD in 2015. Prevalence rises steeply with age, from under 2 percent in young adults to roughly one in seven people in their late eighties.
Peripheral artery disease matters beyond the legs. People with PAD carry a high risk of heart attack and stroke, because leg plaque is usually a marker of plaque elsewhere. Many cases are silent. Only a minority of people with PAD describe the textbook pattern of calf pain on walking, and others simply slow down, walk less, and blame stiffness or getting older.
Estimated PAD prevalence by age, % of adults
Approximate, simplified from Song P et al., Lancet Global Health 2019 (global estimates). Rounded.
PAD prevalence roughly doubles with each two decades of age.
Why does PAD overlap so much with the people who use GLP-1 drugs?
Peripheral artery disease overlaps with GLP-1 use because both are driven by the same metabolic risk factors: type 2 diabetes, high blood pressure, abnormal cholesterol, and excess weight. Smoking is the strongest single risk factor. In the Song meta-analysis, current smokers had close to three times the odds of PAD, and people with diabetes had nearly twice the odds.
Diabetes also changes how PAD behaves. People with diabetes tend to develop disease further down the leg, in the arteries below the knee, and nerve damage can blunt the pain that would otherwise warn of poor blood flow. That combination is why diabetic foot wounds and amputations cluster in this group. Our article on insulin sensitivity and blood sugar covers the glucose side of the picture.
Approximate odds of PAD by risk factor
Rounded pooled odds ratios from Song P et al., Lancet Global Health 2019. 1.0 = no added risk.
Smoking outweighs every metabolic factor, which is why quitting is the first step in every PAD guideline.
How is PAD diagnosed?
Peripheral artery disease is usually diagnosed with the ankle-brachial index, a five-minute test that divides the systolic blood pressure at the ankle by the pressure in the arm. In healthy legs, ankle pressure is equal to or slightly higher than arm pressure. A ratio of 0.90 or lower means less blood is reaching the ankle and is consistent with PAD under the 2024 ACC/AHA guideline.
| Resting ABI | Interpretation | Practical note |
|---|---|---|
| Above 1.40 | Noncompressible arteries | Stiff, calcified vessels, common in long-standing diabetes and kidney disease. A toe-brachial index is usually needed. |
| 1.00 to 1.40 | Normal | PAD is unlikely at rest, though exercise testing can still be useful if symptoms are typical. |
| 0.91 to 0.99 | Borderline | Often repeated or followed by an exercise ABI. |
| 0.90 or below | Consistent with PAD | Lower values indicate more severe narrowing. Values near 0.40 or below suggest severe disease. |
The ankle-brachial index has a known blind spot in diabetes. Calcified arteries resist compression by the cuff and can read falsely normal or high, so a toe-brachial index or duplex ultrasound is often added. Anyone with diabetes, a smoking history, and leg symptoms on walking is a reasonable candidate to ask about the test.
What did the STRIDE trial find about semaglutide and walking?
The STRIDE trial found that semaglutide 1.0 mg once weekly improved maximum walking distance in people with type 2 diabetes and claudication by about 13 percent more than placebo after 52 weeks. Marc Bonaca and colleagues published the results in The Lancet in 2025. The trial enrolled 792 adults with early symptomatic PAD and measured walking on a constant-load treadmill.
The estimated treatment ratio for maximum walking distance was 1.13, with a 95 percent confidence interval of 1.06 to 1.21. Pain-free walking distance and scores on a PAD-specific quality-of-life questionnaire also moved in favour of semaglutide. For context, very few drugs have improved walking in claudication. Cilostazol, approved in the United States in 1999, produces modest gains and cannot be used by people with heart failure.
Maximum walking distance at week 52, indexed to placebo
Bonaca MP et al., Lancet 2025 (STRIDE, n=792). Placebo set to 100. Estimated treatment ratio 1.13.
The chart shows the relative difference between groups, not absolute meters walked.
How might a GLP-1 drug improve leg circulation?
Researchers have proposed several ways a GLP-1 drug might improve walking in PAD, and none has been proven to be the main one. Weight loss reduces the work the legs have to do with each step. GLP-1 receptor agonists also lower markers of inflammation such as C-reactive protein, improve blood pressure, glucose, and lipids, and in laboratory studies improve the function of the endothelium, the inner lining of blood vessels.
Semaglutide already has outcome data on the arteries of the heart and brain. The SELECT trial, published in the New England Journal of Medicine in 2023, followed 17,604 adults with cardiovascular disease and overweight but no diabetes, and found 20 percent fewer major cardiovascular events on semaglutide 2.4 mg. STRIDE extends that picture to the legs, but only for people with diabetes. Our article on cardiovascular and heart health covers SELECT in detail, and our inflammation article covers the CRP data.
Do GLP-1 drugs raise or lower amputation risk?
GLP-1 receptor agonists have not raised amputation risk in large outcome trials, and one analysis suggests a lower risk. In a post hoc analysis of the LEADER trial of liraglutide, published in Diabetes Care in 2018 by Ketan Dhatariya and colleagues, amputations were less frequent with liraglutide than placebo, with a hazard ratio of about 0.65. Post hoc results like this generate hypotheses rather than settle them.
The question matters because a different diabetes drug class raised alarms. In the CANVAS program, published in the New England Journal of Medicine in 2017, the SGLT2 inhibitor canagliflozin was linked to roughly double the rate of lower-limb amputation compared with placebo. Later trials of other SGLT2 inhibitors have not shown the same signal, but people with established PAD and foot problems often have their diabetes medications reviewed with this history in mind.
Hazard ratio for lower-limb amputation vs placebo
LEADER: Dhatariya K et al., Diabetes Care 2018. CANVAS: Neal B et al., NEJM 2017. Separate trials, not a head-to-head comparison.
Values left of the dashed line indicate lower risk than placebo; values to the right indicate higher risk.
Does any of this apply to a GLP-1 microdose?
The STRIDE findings do not directly apply to a GLP-1 microdose, because no trial has tested low-dose semaglutide or tirzepatide in peripheral artery disease. STRIDE used 1.0 mg of semaglutide a week, a standard maintenance dose for type 2 diabetes. Microdose protocols commonly use a fraction of that, and the dose-response for walking distance is unknown.
Some of the proposed mechanisms, such as small improvements in blood pressure and glucose, appear at lower doses in other settings. Others, such as weight loss, scale with dose. A reasonable reading is that a microdose might support the general cardiometabolic risk factors that feed PAD, but it has not been shown to change walking distance, limb outcomes, or plaque. People with diagnosed PAD should treat a GLP-1 protocol as one part of a plan their vascular or primary care clinician oversees, not as a substitute for proven treatment. For dose context, see our microdosing guide.
What actually improves walking distance in PAD?
Supervised exercise therapy is the treatment with the strongest evidence for improving walking distance in claudication. The 2024 ACC/AHA guideline recommends sessions of 30 to 45 minutes, at least three times a week, for at least 12 weeks. Patients walk until claudication pain is moderate, rest until it fades, and repeat, gradually building the total time spent walking.
Walking through moderate discomfort sounds counterintuitive, but the repeated stress appears to drive collateral vessel growth and better oxygen use in the calf muscles. Structured home walking programmes are a recognized alternative when supervised programmes are not available. Alongside exercise, the guideline foundations are quitting smoking, a statin, an antiplatelet drug, and blood pressure and glucose control. Our article on exercise and training covers pairing activity with a GLP-1 protocol.
Active walking minutes per session across a 12-week programme
Illustrative progression based on the structure in the 2024 ACC/AHA PAD guideline. Not an exercise prescription.
Rest breaks are not counted. The goal is more total walking time per session, not a faster pace.
Which leg symptoms need urgent attention?
Leg symptoms need urgent attention when pain appears at rest, when a foot wound will not heal, or when a leg suddenly turns cold, pale, numb, or weak. Pain in the foot at night that eases when the leg hangs over the side of the bed is a sign of chronic limb-threatening ischemia. A sudden cold, painful leg can be acute limb ischemia, which needs emergency care within hours.
Weight loss on a GLP-1 can also change how shoes fit and how the feet bear load. People with diabetes and PAD should check their feet daily for blisters, cuts, and colour changes, and see a podiatrist if anything does not heal within a week or two. The electrician from the introduction now walks the dog in three timed laps a day and logs the distance before calf pain starts.
What is the takeaway?
The takeaway is that semaglutide at 1.0 mg improved walking distance in people with diabetes and claudication in a large 2025 trial, and GLP-1 drugs have not shown the amputation signal seen with canagliflozin. Those are full-dose findings in people with diabetes. A microdose protocol has not been studied in PAD. For anyone with calf pain on walking, the useful steps are an ankle-brachial index, quitting smoking, a structured walking programme, and a conversation with a clinician about where a GLP-1 medication fits.
"Calf pain that stops a walk at the same spot every time is information. It is worth a five-minute test before anyone calls it age."
Frequently asked questions
Can GLP-1 medications help peripheral artery disease?
One large randomized trial suggests a GLP-1 medication can improve walking in people with peripheral artery disease and type 2 diabetes. The STRIDE trial, published in The Lancet in 2025, found that semaglutide 1.0 mg weekly increased maximum walking distance by about 13 percent more than placebo over 52 weeks. The trial did not test people without diabetes or anyone on a microdose protocol.
What was the STRIDE trial?
STRIDE was a phase 3b randomized, double-blind trial of 792 adults with type 2 diabetes and symptomatic peripheral artery disease with intermittent claudication. Participants took semaglutide 1.0 mg or placebo once a week for 52 weeks. The main outcome was the change in maximum walking distance on a treadmill, and pain-free walking distance and quality of life also favoured semaglutide.
Does a GLP-1 microdose improve leg circulation?
No study has tested whether a GLP-1 microdose improves leg circulation or walking distance. The STRIDE result came from semaglutide 1.0 mg, which is several times higher than doses typically used in microdose protocols. Any effect at lower doses is unknown, and a microdose should not be treated as a therapy for peripheral artery disease.
What are the first signs of peripheral artery disease?
The classic first sign of peripheral artery disease is intermittent claudication, a cramping or aching pain in the calf, thigh, or buttock that comes on with walking and eases within a few minutes of rest. Many people have no leg symptoms at all, or have atypical symptoms such as leg fatigue or slower walking. Cold feet, shiny skin, hair loss on the shins, and slow-healing foot sores can also be signs.
How is peripheral artery disease diagnosed?
Peripheral artery disease is usually diagnosed with the ankle-brachial index, which compares blood pressure at the ankle with blood pressure in the arm. A value of 0.90 or lower is consistent with PAD. People with diabetes or kidney disease may have stiff arteries that give falsely high readings, so a toe-brachial index or imaging may be needed.
Do GLP-1 drugs increase amputation risk?
GLP-1 receptor agonists have not shown an amputation risk signal in the large outcome trials. In a post hoc analysis of the LEADER trial, liraglutide was associated with a lower risk of amputation than placebo, with a hazard ratio of about 0.65. That differs from canagliflozin, an SGLT2 inhibitor that showed roughly double the amputation risk in the CANVAS program.
Is walking still important if you take a GLP-1 for PAD?
Walking remains the most important non-drug therapy for peripheral artery disease regardless of medication. Supervised exercise therapy, typically 30 to 45 minutes three times a week for at least 12 weeks, is a first-line recommendation in the 2024 ACC/AHA guideline. Exercise programmes have generally produced larger walking gains than drug therapy.
When is leg pain an emergency?
Leg pain is an emergency when it starts suddenly and comes with a cold, pale, numb, or weak foot or leg, which can signal acute limb ischemia. Pain in the foot at rest, especially at night, and wounds on the feet or toes that do not heal are also urgent warning signs. These symptoms need same-day medical care rather than a change in medication or exercise.
Clinical references
- Bonaca MP, Catarig AM, Houlind K, et al. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. Lancet. 2025.
- Song P, Rudan D, Zhu Y, et al. Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. Lancet Global Health. 2019;7(8):e1020-e1030.
- Gornik HL, Aronow HD, Goodney PP, et al. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS guideline for the management of lower extremity peripheral artery disease. Circulation. 2024;149(24):e1313-e1410.
- Dhatariya K, Bain SC, Buse JB, et al. The impact of liraglutide on diabetes-related foot ulceration and associated complications in patients with type 2 diabetes at high risk for cardiovascular events: results from the LEADER trial. Diabetes Care. 2018;41(10):2229-2235.
- Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. New England Journal of Medicine. 2017;377(7):644-657.
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). New England Journal of Medicine. 2023;389(24):2221-2232.
- Lane R, Harwood A, Watson L, Leng GC. Exercise for intermittent claudication. Cochrane Database of Systematic Reviews. 2017;12:CD000990.
Medical disclaimer. This article is for general educational and informational purposes only. It is not medical advice and not a substitute for the prescriber, vascular specialist, or clinician responsible for your care. The STRIDE trial enrolled adults with type 2 diabetes taking semaglutide 1.0 mg, and its results have not been tested in people without diabetes or in GLP-1 microdose protocols. No GLP-1 medication should be considered a treatment for peripheral artery disease outside a prescriber's advice. The walking progression chart and the case described in this article are illustrations and do not describe any real individual or predict any outcome. GLP-1 microdosing is an off-label approach and should only be undertaken under a prescriber's supervision. Sudden leg pain, a cold or pale foot, pain at rest, or a non-healing foot wound needs prompt medical care. Do not start, stop, or change any medication without talking to your prescriber.